NEW YORK — Already in late-stage clinical trials, temtokibart, an interleukin (IL)-22 inhibitor, has demonstrated broad activity against multiple markers of inflammation, pruritus, and impaired ...
A study reported in Proceedings of the National Academy of Sciences (PNAS) shows how the presence of a specific protein called IL-22BP affects the composition of the gut microbiota and the body’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results